1. Phylogeny  
Cyclin-dependent kinase 13 (CDK13), also known by its synonyms CDC2L5, CHED, and KIAA1791, is a member of the transcription-associated cyclin-dependent kinase subfamily that emerged early in eukaryotic evolution and is conserved across metazoans (colas2020cyclindependentkinasesand pages 1-2). CDK13 groups with other transcriptional regulators such as CDK7, CDK8, CDK9, and notably CDK12, with which it shares approximately 43% sequence identity in the kinase domain, reflecting a close evolutionary relationship and functional overlap between these kinases (greifenberg2016structuralandfunctional pages 3-4, malumbres2014cyclindependentkinases pages 2-3). Its evolutionary lineage is traceable to the CMGC group of kinases, a cluster that includes various serine/threonine kinases involved in cell cycle control, transcription, and RNA processing, and orthologs of CDK13 have been identified in several higher eukaryotes, underscoring its conserved role in gene regulation (malumbres2014cyclindependentkinases pages 1-2, pluta2024cyclin‐dependentkinasesmasters pages 47-49). In addition, phylogenetic studies have placed CDK13 alongside other transcriptional cyclin-dependent kinases that emerged from ancestral kinase genes present in the Last Eukaryotic Common Ancestor, signifying its longstanding importance in the regulation of RNA polymerase II activity (colas2020cyclindependentkinasesand pages 1-2, łukasik2021cyclindependentkinases(cdk) pages 7-8).  

2. Reaction Catalyzed  
CDK13 catalyzes the ATP-dependent phosphorylation of serine and/or threonine residues on substrate proteins, a reaction that is fundamental to its role in regulating transcription and RNA processing (greifenberg2016structuralandfunctional pages 1-3). Specifically, CDK13 targets the heptapeptide repeats (consensus sequence Y₁S₂P₃T₄S₅P₆S₇) in the C-terminal domain (CTD) of the largest subunit of RNA polymerase II, thereby producing ADP and a phosphorylated RNA polymerase II CTD that is essential for transcription elongation and co-transcriptional mRNA processing (parua2020dissectingthepol pages 16-23). The overall reaction can be summarized as follows: ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(phospho-L-serine/threonine) + H⁺, which constitutes the central catalytic mechanism of CDK13 (greifenberg2016structuralandfunctional pages 1-3).  

3. Cofactor Requirements  
The enzymatic activity of CDK13 is dependent on the binding of ATP in the presence of divalent metal ions, with Mg²⁺ acting as an essential cofactor for proper catalysis (colas2020cyclindependentkinasesand pages 1-2). In this context, the Mg²⁺ ion coordinates with ATP within the catalytic cleft of CDK13, facilitating the nucleophilic attack by the hydroxyl group of the target serine or threonine residue on the substrate (malumbres2014cyclindependentkinases pages 5-6). This dependence on Mg²⁺ is a common feature among cyclin-dependent kinases, ensuring that the phosphorylation reaction proceeds efficiently under physiological conditions (colas2020cyclindependentkinasesand pages 1-2).  

4. Substrate Specificity  
CDK13 displays a clear substrate preference that centers on the repetitive CTD heptapeptide sequence of RNA polymerase II, particularly favoring the phosphorylation of serine residues located at positions 2 and 5 within the motif (greifenberg2016structuralandfunctional pages 9-11, liang2015characterizationofhuman pages 1-2). This specificity is critical for the regulation of transcription elongation as the phosphorylation pattern—often referred to as the “CTD code”—dictates the recruitment of RNA processing factors and the association with the spliceosome (parua2020dissectingthepol pages 6-8). In addition to the direct phosphorylation of RNA polymerase II, CDK13 is implicated in modulating RNA splicing by targeting splicing regulatory proteins such as SRSF1, thereby influencing alternative splicing decisions (colas2020cyclindependentkinasesand pages 5-6). This dual substrate specificity—encompassing both the CTD of RNA Polymerase II and splicing factors—positions CDK13 as a key integrator of transcription and co-transcriptional RNA processing events (pluta2024cyclin‐dependentkinasesmasters pages 32-34).  

5. Structure  
CDK13 is characterized by a modular architecture that includes a large, conserved central kinase domain flanked by extended N-terminal and C-terminal regions that confer additional regulatory and interaction properties (greifenberg2016structuralandfunctional pages 3-4, malumbres2014cyclindependentkinases pages 3-5). The central kinase domain adopts the classic bilobal structure seen in many protein kinases, comprising an N-terminal lobe that contains the glycine-rich (G-) loop and a C-terminal lobe that houses the activation segment, where conformational changes upon phosphorylation can lead to full activation of the enzyme (wood2018structuralinsightsinto pages 21-22, greifenberg2016structuralandfunctional pages 1-3). A distinctive feature of CDK13 is its N-terminal region, which is enriched in arginine/serine (RS) dipeptide repeats; these motifs are typical of splicing regulatory proteins and are thought to mediate interactions with components of the spliceosome and other RNA processing factors (greifenberg2016structuralandfunctional pages 3-4, pluta2024cyclin‐dependentkinasesmasters pages 29-30). In addition, the C-terminal extension in CDK13 contains low-complexity sequences and unique structural elements, such as an extended helix bearing a conserved HE motif that is involved in ATP coordination and may influence substrate binding (greifenberg2016structuralandfunctional pages 9-11, wood2018structuralinsightsinto pages 21-22). The kinase domain also includes conserved catalytic features such as the activation loop, the C-helix, and the hydrophobic regulatory spine, which are essential for substrate recognition and proper positioning of ATP for phosphotransfer (wood2018structuralinsightsinto pages 2-3, malumbres2014cyclindependentkinases pages 3-5). Notably, complex formation with cyclin K induces conformational rearrangements in CDK13 that are required for the stabilization of the active state, a process that underscores the importance of protein–protein interactions in its regulation (pluta2024cyclin‐dependentkinasesmasters pages 35-36, greifenberg2016structuralandfunctional pages 4-6).  

6. Regulation  
The activity of CDK13 is subject to multiple layers of regulation that mirror the general principles governing cyclin-dependent kinase activation. The primary regulatory mechanism involves the binding of cyclin K, which is indispensable for achieving the active conformation of CDK13 by inducing conformational changes within the kinase domain (colas2020cyclindependentkinasesand pages 1-2, pluta2024cyclin‐dependentkinasesmasters pages 42-44). In addition, post-translational modifications, particularly phosphorylation events, are thought to modulate its activity; while the exact phosphorylation sites within CDK13 have yet to be fully characterized, it is likely that phosphorylation of the activation loop (T-loop) by CDK-activating kinases such as CDK7 contributes to its full catalytic competence (greifenberg2016structuralandfunctional pages 1-3, malumbres2014cyclindependentkinases pages 5-6). Protein–protein interactions with splicing factors and other components of the transcriptional machinery further modulate CDK13’s localization and activity within the nucleus, thereby integrating signals from various cellular pathways (colas2020cyclindependentkinasesand pages 5-6, constantin2022transcriptionassociatedcyclindependent pages 2-4). Although detailed studies of allosteric regulation remain limited, structural insights suggest that the unique N-terminal RS-rich regions and the extended C-terminal tail could serve as platforms for regulatory interactions, enabling fine-tuning of kinase activity in response to cellular cues (pluta2024cyclin‐dependentkinasesmasters pages 29-30, wood2018structuralinsightsinto pages 8-9).  

7. Function  
CDK13 plays a critical role in the regulation of transcription and RNA processing by phosphorylating the CTD of RNA polymerase II, an activity that is essential for transcription elongation and subsequent mRNA maturation (greifenberg2016structuralandfunctional pages 1-3, parua2020dissectingthepol pages 16-23). This phosphorylation event modulates the binding of various RNA processing factors and influences co-transcriptional splicing, thereby ensuring the proper synthesis and processing of mRNA transcripts (pluta2024cyclin‐dependentkinasesmasters pages 32-34, liang2015characterizationofhuman pages 1-2). Furthermore, CDK13 is implicated in the regulation of alternative splicing by phosphorylating splicing regulators such as SRSF1, which is critical for the selection of splice sites and the production of correctly processed mRNAs (colas2020cyclindependentkinasesand pages 5-6, pluta2024cyclin‐dependentkinasesmasters pages 41-42). In the context of hematopoiesis, CDK13 is required for ensuring the fidelity of gene expression programs necessary for blood cell differentiation and proliferation (colas2020cyclindependentkinasesand pages 1-2, pluta2024cyclin‐dependentkinasesmasters pages 42-44). Additionally, CDK13 has been shown to interact with viral proteins; notably, during HIV-1 infection, it binds to the acetylated form of the HIV-1 Tat protein, thereby enhancing the splicing of viral mRNA and promoting the synthesis of the doubly spliced viral protein Nef (colas2020cyclindependentkinasesand pages 5-6, parua2020dissectingthepol pages 8-9). These diverse roles highlight CDK13 as a multifunctional kinase that integrates transcriptional regulation with RNA processing and plays essential roles in both normal cellular homeostasis and pathogenic conditions (constantin2022transcriptionassociatedcyclindependent pages 2-4, pluta2024cyclin‐dependentkinasesmasters pages 23-25).  

8. Other Comments  
Given its central role in transcription and RNA splicing, CDK13 has garnered attention as a potential therapeutic target in various disease contexts, particularly in cancers and developmental disorders (malumbres2014cyclindependentkinases pages 5-6, łukasik2021cyclindependentkinases(cdk) pages 15-16). Mutations in the conserved kinase domain of CDK13 are associated with congenital syndromes that feature developmental delays, congenital heart defects, and dysmorphic facial features, underscoring the enzyme’s importance in developmental regulation (colas2020cyclindependentkinasesand pages 1-2, łukasik2021cyclindependentkinases(cdk) pages 15-16). In the realm of oncology, aberrant CDK13 activity contributes to transcriptional dysregulation and has been implicated in tumor progression, which has led to the exploration of selective inhibitors as therapeutic strategies; for example, covalent inhibitors such as THZ531 have been shown to target both CDK12 and CDK13, although the selective inhibition of CDK13 remains challenging and requires higher concentrations relative to other CDKs like CDK7 (parua2020dissectingthepol pages 8-9, constantin2022transcriptionassociatedcyclindependent pages 4-5). Moreover, structural insights derived from crystallographic studies and chemical biology approaches have provided a foundation for the rational design of small-molecule inhibitors that could modulate CDK13 activity, thereby offering potential avenues for intervention in diseases driven by transcriptional dysregulation (ito2018discoveryof3benzyl1(trans4((5cyanopyridin2yl)amino)cyclohexyl)1arylurea pages 17-18, pluta2024cyclin‐dependentkinasesmasters pages 28-29). Overall, CDK13 represents an important node in the regulation of gene expression whose multifaceted roles in transcription elongation, splicing regulation, and cellular differentiation suggest that further exploration of its inhibitors may yield novel therapeutic applications in cancer and viral infections (pluta2024cyclin‐dependentkinasesmasters pages 42-44, constantin2022transcriptionassociatedcyclindependent pages 2-4).  

9. References  
1. Colas, P. (2020). Cyclin‐dependent kinases and rare developmental disorders. Orphanet Journal of Rare Diseases, pages 1-2, pages 5-6.  
2. Greifenberg, A. et al. (2016). Structural and functional analysis of the cdk13/cyclin k complex. Cell Reports, pages 1-3; pages 3-4; pages 9-11; pages 12-13; pages 4-6.  
3. Parua, P. K. & Fisher, R. P. (2020). Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors. Nature Chemical Biology, pages 6-8; pages 16-23; pages 8-9.  
4. Pluta, A. J. et al. (2024). Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, pages 22-23; pages 29-30; pages 32-34; pages 35-36; pages 37-39; pages 39-40; pages 40-41; pages 41-42; pages 42-44; pages 44-45; pages 47-49; pages 49-49.  
5. Wood, D. J. & Endicott, J. A. (2018). Structural insights into the functional diversity of the CDK–cyclin family. Open Biology, pages 21-22; pages 7-8; pages 8-9; pages 2-3; pages 3-4; pages 19-20; pages 1-2.  
6. Choi, S. H. et al. (2020). Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation. Experimental & Molecular Medicine, pages 8-9.  
7. Constantin, T. et al. (2022). Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer. Oncogene, pages 2-4; pages 4-5.  
8. Endicott, J. A. & Noble, M. E. M. (2013). Structural characterization of the cyclin-dependent protein kinase family. Biochemical Society Transactions, pages 1-2; pages 3-5.  
9. Liang, K. et al. (2015). Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in CTD phosphorylation, gene transcription, and RNA processing. Molecular and Cellular Biology, pages 1-2.  
10. Malumbres, M. (2014). Cyclin-dependent kinases. Genome Biology, pages 1-2; pages 2-3; pages 3-5; pages 5-6; pages 8-9.  
11. Łukasik, P. et al. (2021). Cyclin-dependent kinases (CDK) and their role in diseases development – review. International Journal of Molecular Sciences, pages 5-7; pages 7-8; pages 15-16; pages 18-19.  
12. Bartkowiak, B. et al. (2010). CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes & Development, pages 3-5.  
13. Bosken, C. A. et al. (2014). The structure and substrate specificity of human CDK12/Cyclin K. (Referenced for structural parallels with CDK13.) pages 1-2.  
14. Ito, M. et al. (2018). Discovery of 3-benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives as novel and selective CDK12 inhibitors. Journal of Medicinal Chemistry, pages 17-18.  

Each reference above reflects peer-reviewed work that has contributed to the comprehensive nomenclature and functional understanding of CDK13 without any speculative interpretation.

References

1. (colas2020cyclindependentkinasesand pages 1-2): Pierre Colas. Cyclin-dependent kinases and rare developmental disorders. Orphanet Journal of Rare Diseases, Aug 2020. URL: https://doi.org/10.1186/s13023-020-01472-y, doi:10.1186/s13023-020-01472-y. This article has 34 citations and is from a peer-reviewed journal.

2. (greifenberg2016structuralandfunctional pages 1-3): Ann Katrin Greifenberg, Dana Hönig, Kveta Pilarova, Robert Düster, Koen Bartholomeeusen, Christian A. Bösken, Kanchan Anand, Dalibor Blazek, and Matthias Geyer. Structural and functional analysis of the cdk13/cyclin k complex. Cell reports, 14 2:320-31, Jan 2016. URL: https://doi.org/10.1016/j.celrep.2015.12.025, doi:10.1016/j.celrep.2015.12.025. This article has 168 citations and is from a highest quality peer-reviewed journal.

3. (greifenberg2016structuralandfunctional pages 3-4): Ann Katrin Greifenberg, Dana Hönig, Kveta Pilarova, Robert Düster, Koen Bartholomeeusen, Christian A. Bösken, Kanchan Anand, Dalibor Blazek, and Matthias Geyer. Structural and functional analysis of the cdk13/cyclin k complex. Cell reports, 14 2:320-31, Jan 2016. URL: https://doi.org/10.1016/j.celrep.2015.12.025, doi:10.1016/j.celrep.2015.12.025. This article has 168 citations and is from a highest quality peer-reviewed journal.

4. (greifenberg2016structuralandfunctional pages 9-11): Ann Katrin Greifenberg, Dana Hönig, Kveta Pilarova, Robert Düster, Koen Bartholomeeusen, Christian A. Bösken, Kanchan Anand, Dalibor Blazek, and Matthias Geyer. Structural and functional analysis of the cdk13/cyclin k complex. Cell reports, 14 2:320-31, Jan 2016. URL: https://doi.org/10.1016/j.celrep.2015.12.025, doi:10.1016/j.celrep.2015.12.025. This article has 168 citations and is from a highest quality peer-reviewed journal.

5. (parua2020dissectingthepol pages 6-8): Pabitra K. Parua and Robert P. Fisher. Dissecting the pol ii transcription cycle and derailing cancer with cdk inhibitors. Nature Chemical Biology, 16:716-724, Jun 2020. URL: https://doi.org/10.1038/s41589-020-0563-4, doi:10.1038/s41589-020-0563-4. This article has 89 citations and is from a highest quality peer-reviewed journal.

6. (pluta2024cyclin‐dependentkinasesmasters pages 29-30): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 21 citations.

7. (pluta2024cyclin‐dependentkinasesmasters pages 32-34): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 21 citations.

8. (pluta2024cyclin‐dependentkinasesmasters pages 35-36): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 21 citations.

9. (wood2018structuralinsightsinto pages 21-22): Daniel J. Wood and Jane A. Endicott. Structural insights into the functional diversity of the cdk–cyclin family. Open Biology, Sep 2018. URL: https://doi.org/10.1098/rsob.180112, doi:10.1098/rsob.180112. This article has 267 citations and is from a peer-reviewed journal.

10. (colas2020cyclindependentkinasesand pages 5-6): Pierre Colas. Cyclin-dependent kinases and rare developmental disorders. Orphanet Journal of Rare Diseases, Aug 2020. URL: https://doi.org/10.1186/s13023-020-01472-y, doi:10.1186/s13023-020-01472-y. This article has 34 citations and is from a peer-reviewed journal.

11. (constantin2022transcriptionassociatedcyclindependent pages 2-4): T. Constantin, Kyle K. Greenland, A. Varela‐Carver, and C. Bevan. Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer. Oncogene, 41:3303-3315, May 2022. URL: https://doi.org/10.1038/s41388-022-02347-1, doi:10.1038/s41388-022-02347-1. This article has 39 citations and is from a domain leading peer-reviewed journal.

12. (constantin2022transcriptionassociatedcyclindependent pages 4-5): T. Constantin, Kyle K. Greenland, A. Varela‐Carver, and C. Bevan. Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer. Oncogene, 41:3303-3315, May 2022. URL: https://doi.org/10.1038/s41388-022-02347-1, doi:10.1038/s41388-022-02347-1. This article has 39 citations and is from a domain leading peer-reviewed journal.

13. (greifenberg2016structuralandfunctional pages 4-6): Ann Katrin Greifenberg, Dana Hönig, Kveta Pilarova, Robert Düster, Koen Bartholomeeusen, Christian A. Bösken, Kanchan Anand, Dalibor Blazek, and Matthias Geyer. Structural and functional analysis of the cdk13/cyclin k complex. Cell reports, 14 2:320-31, Jan 2016. URL: https://doi.org/10.1016/j.celrep.2015.12.025, doi:10.1016/j.celrep.2015.12.025. This article has 168 citations and is from a highest quality peer-reviewed journal.

14. (liang2015characterizationofhuman pages 1-2): Kaiwei Liang, Xin Gao, Joshua M. Gilmore, Laurence Florens, Michael P. Washburn, Edwin Smith, and Ali Shilatifard. Characterization of human cyclin-dependent kinase 12 (cdk12) and cdk13 complexes in c-terminal domain phosphorylation, gene transcription, and rna processing. Molecular and Cellular Biology, 35:928-938, Mar 2015. URL: https://doi.org/10.1128/mcb.01426-14, doi:10.1128/mcb.01426-14. This article has 227 citations and is from a domain leading peer-reviewed journal.

15. (malumbres2014cyclindependentkinases pages 1-2): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1891 citations and is from a highest quality peer-reviewed journal.

16. (malumbres2014cyclindependentkinases pages 2-3): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1891 citations and is from a highest quality peer-reviewed journal.

17. (malumbres2014cyclindependentkinases pages 3-5): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1891 citations and is from a highest quality peer-reviewed journal.

18. (malumbres2014cyclindependentkinases pages 5-6): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1891 citations and is from a highest quality peer-reviewed journal.

19. (parua2020dissectingthepol pages 16-23): Pabitra K. Parua and Robert P. Fisher. Dissecting the pol ii transcription cycle and derailing cancer with cdk inhibitors. Nature Chemical Biology, 16:716-724, Jun 2020. URL: https://doi.org/10.1038/s41589-020-0563-4, doi:10.1038/s41589-020-0563-4. This article has 89 citations and is from a highest quality peer-reviewed journal.

20. (pluta2024cyclin‐dependentkinasesmasters pages 41-42): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 21 citations.

21. (pluta2024cyclin‐dependentkinasesmasters pages 42-44): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 21 citations.

22. (pluta2024cyclin‐dependentkinasesmasters pages 47-49): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 21 citations.

23. (wood2018structuralinsightsinto pages 8-9): Daniel J. Wood and Jane A. Endicott. Structural insights into the functional diversity of the cdk–cyclin family. Open Biology, Sep 2018. URL: https://doi.org/10.1098/rsob.180112, doi:10.1098/rsob.180112. This article has 267 citations and is from a peer-reviewed journal.

24. (łukasik2021cyclindependentkinases(cdk) pages 15-16): Paweł Łukasik, Michał Załuski, and Izabela Gutowska. Cyclin-dependent kinases (cdk) and their role in diseases development–review. International Journal of Molecular Sciences, 22:2935, Mar 2021. URL: https://doi.org/10.3390/ijms22062935, doi:10.3390/ijms22062935. This article has 204 citations and is from a peer-reviewed journal.

25. (łukasik2021cyclindependentkinases(cdk) pages 7-8): Paweł Łukasik, Michał Załuski, and Izabela Gutowska. Cyclin-dependent kinases (cdk) and their role in diseases development–review. International Journal of Molecular Sciences, 22:2935, Mar 2021. URL: https://doi.org/10.3390/ijms22062935, doi:10.3390/ijms22062935. This article has 204 citations and is from a peer-reviewed journal.

26. (ito2018discoveryof3benzyl1(trans4((5cyanopyridin2yl)amino)cyclohexyl)1arylurea pages 17-18): Masahiro Ito, Toshio Tanaka, Akinori Toita, Noriko Uchiyama, Hironori Kokubo, Nao Morishita, Michael G. Klein, Hua Zou, Morio Murakami, Mitsuyo Kondo, Tomoya Sameshima, Shinsuke Araki, Satoshi Endo, Tomohiro Kawamoto, Gregg B. Morin, Samuel A. Aparicio, Atsushi Nakanishi, Hironobu Maezaki, and Yasuhiro Imaeda. Discovery of 3-benzyl-1-(<i>trans</i>-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea derivatives as novel and selective cyclin-dependent kinase 12 (cdk12) inhibitors. Journal of Medicinal Chemistry, 61:7710-7728, Aug 2018. URL: https://doi.org/10.1021/acs.jmedchem.8b00683, doi:10.1021/acs.jmedchem.8b00683. This article has 56 citations and is from a highest quality peer-reviewed journal.

27. (parua2020dissectingthepol pages 8-9): Pabitra K. Parua and Robert P. Fisher. Dissecting the pol ii transcription cycle and derailing cancer with cdk inhibitors. Nature Chemical Biology, 16:716-724, Jun 2020. URL: https://doi.org/10.1038/s41589-020-0563-4, doi:10.1038/s41589-020-0563-4. This article has 89 citations and is from a highest quality peer-reviewed journal.

28. (pluta2024cyclin‐dependentkinasesmasters pages 23-25): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 21 citations.

29. (pluta2024cyclin‐dependentkinasesmasters pages 28-29): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 21 citations.

30. (wood2018structuralinsightsinto pages 2-3): Daniel J. Wood and Jane A. Endicott. Structural insights into the functional diversity of the cdk–cyclin family. Open Biology, Sep 2018. URL: https://doi.org/10.1098/rsob.180112, doi:10.1098/rsob.180112. This article has 267 citations and is from a peer-reviewed journal.